Boukpessi Tchilalo, Hoac Betty, Coyac Benjamin R, Leger Thibaut, Garcia Camille, Wicart Philippe, Whyte Michael P, Glorieux Francis H, Linglart Agnès, Chaussain Catherine, McKee Marc D
Faculty of Dentistry, McGill University, Montreal, QC, Canada; EA 2496, Laboratory of Orofacial Pathologies, Imaging and Biotherapies, School of Dentistry University Paris Descartes Sorbonne Paris Cité, Paris, France; AP-HP Department of Odontology, Charles Foix and Bretonneau Hospitals, Reference Center for Rare Diseases of Calcium and Phosphorus Metabolism, Paris, France.
Faculty of Dentistry, McGill University, Montreal, QC, Canada.
Bone. 2017 Feb;95:151-161. doi: 10.1016/j.bone.2016.11.019. Epub 2016 Nov 21.
Seven young patients with X-linked hypophosphatemia (XLH, having inactivating PHEX mutations) were discovered to accumulate osteopontin (OPN) at the sites of defective bone mineralization near osteocytes - the so-called hallmark periosteocytic (lacunar) "halos" of XLH. OPN was also localized in the pericanalicular matrix extending beyond the osteocyte lacunae, as well as in the hypomineralized matrix of tooth dentin. OPN, a potent inhibitor of mineralization normally degraded by PHEX, is a member of a family of acidic, phosphorylated, calcium-binding, extracellular matrix proteins known to regulate dental, skeletal, and pathologic mineralization. Associated with the increased amount of OPN (along with inhibitory OPN peptide fragments) in XLH bone matrix, we found an enlarged, hypomineralized, lacuno-canalicular network - a defective pattern of skeletal mineralization that decreases stiffness locally at: i) the cell-matrix interface in the pericellular environment of the mechanosensing osteocyte, and ii) the osteocyte's dendritic network of cell processes extending throughout the bone. Our findings of an excess of inhibitory OPN near osteocytes and their cell processes, and in dentin, spatially correlates with the defective mineralization observed at these sites in the skeleton and teeth of XLH patients. These changes likely contribute to the dento-osseous pathobiology of XLH, and participate in the aberrant bone adaptation and remodeling seen in XLH.
在七名患有X连锁低磷血症(XLH,存在失活的PHEX突变)的年轻患者中,发现骨桥蛋白(OPN)在靠近骨细胞的骨矿化缺陷部位积聚,即XLH所谓的标志性骨细胞周(腔隙)“晕圈”。OPN也定位于延伸至骨细胞腔隙之外的小管周基质以及牙本质的矿化不足基质中。OPN是一种通常由PHEX降解的矿化强效抑制剂,是已知调节牙齿、骨骼和病理性矿化的酸性、磷酸化、钙结合细胞外基质蛋白家族的成员。与XLH骨基质中OPN(以及抑制性OPN肽片段)含量增加相关,我们发现了一个扩大的、矿化不足的腔隙-小管网络,这是一种骨骼矿化缺陷模式,在以下部位局部降低了硬度:i)机械感受性骨细胞的细胞周环境中的细胞-基质界面,以及ii)贯穿骨骼延伸的骨细胞树突状细胞突起网络。我们发现在骨细胞及其细胞突起附近以及牙本质中有过量的抑制性OPN,这在空间上与XLH患者骨骼和牙齿这些部位观察到的矿化缺陷相关。这些变化可能导致XLH的牙骨病理生物学,并参与XLH中异常的骨适应和重塑。